Long-Term Melatonin Use Tied to Higher Heart Failure Risk in Chronic Insomnia
Long-term melatonin use in people with chronic insomnia was associated with a roughly 90% higher risk of developing heart failure over five years in a large preliminary study. The signal is striking because melatonin is often viewed as a gentle sleep aid, yet chronic nightly use may carry cardiovascular consequences that deserve closer scrutiny rather than casual reassurance.
The finding does not prove melatonin causes heart failure. It does, however, raise a clinically uncomfortable possibility: a supplement widely perceived as low-risk may not be neutral when used for years in patients already living with persistent sleep disruption, a condition itself linked to cardiovascular strain, autonomic imbalance, and metabolic stress.
A Sleep Aid With Cardiovascular Questions Attached
Melatonin is commonly used by people with insomnia because it is available over the counter in many settings and is often marketed as a natural option. That familiarity can flatten risk perception. In routine practice, chronic insomnia patients may reach for melatonin repeatedly, especially when sleep remains fragmented and the next day feels unmanageable. A five-year association with heart failure in that setting is hard to dismiss, even before causality is established.
The reported risk increase was described as roughly 90%, which makes the signal large enough to attract attention from both sleep clinicians and cardiologists. Heart failure develops through a range of pathways, including chronic pressure overload, myocardial injury, neurohormonal activation, and fluid-handling abnormalities. A persistent sleep problem can add physiologic stress on top of those vulnerabilities, and any medication or supplement used nightly in that population should be examined through that lens.
One sentence captures the practical concern: a sleep remedy may not be harmless simply because it is familiar.
Why the Signal Matters in Chronic Insomnia
The relevance is strongest in chronic insomnia, not in occasional sleeplessness after travel, stress, or a temporary schedule change. Patients with long-standing insomnia often cycle through remedies while trying to regain rest and daytime function, and melatonin is frequently viewed as a benign default. A preliminary study suggesting higher long-term heart failure risk changes the tone of that conversation.
Biologically, the concern is less about a single dose and more about prolonged exposure in a population already under physiologic strain. Sleep loss can alter sympathetic tone, blood pressure regulation, glucose control, and inflammatory signaling. If melatonin use is simply a marker of more severe or persistent insomnia, the association could reflect underlying illness burden rather than a drug effect. If the supplement itself contributes, the mechanism remains unclear from the available data, and that uncertainty is exactly why the result matters.
What the Study Does and Does Not Establish
The study was preliminary, and that word carries real weight. Observational signals can be distorted by confounding, reverse causation, and differences in baseline health between people who use a supplement long term and those who do not. People with more severe insomnia may be more likely to take melatonin repeatedly, and severe insomnia itself may track with worse cardiometabolic health.
Even so, a near-doubling of risk over five years is not a trivial fluctuation. Clinicians tend to pay attention when an effect size is this large, especially when the exposure is common and the outcome is serious. The finding should prompt a careful review of how melatonin is being used in chronic insomnia, including duration, dose, and whether patients are receiving evidence-based insomnia treatment rather than depending on indefinite self-treatment.
The signal is not a verdict, but it is strong enough to disrupt complacency.
Bedside Implications for Insomnia Care
For clinicians, the immediate implication is caution around long-term, unsupervised melatonin use in patients with chronic insomnia. A supplement that may help some people fall asleep should not automatically be assumed safe for nightly use over years, especially in patients with known cardiovascular risk factors or symptoms that could mask early heart failure.
For patients, the result argues against treating melatonin as a set-and-forget solution. Persistent insomnia usually deserves a broader assessment, including sleep habits, medication review, mental health factors, sleep-disordered breathing, and cardiovascular risk. If a patient has been taking melatonin for a long time, the conversation should shift from “natural” versus “prescription” to whether the therapy is still necessary, whether it is effective, and whether safer long-term options exist.
The study also reinforces a familiar truth in sleep medicine: treating insomnia is not just about inducing sleep onset. The broader goal is restoring durable, physiologic sleep without creating new downstream problems. When a nightly agent is linked to a serious cardiac outcome, even tentatively, it becomes a candidate for deeper study rather than casual continuation.
What Needs to Happen Next
The next step is not to overreact, but to test the association rigorously. Better studies will need to separate melatonin exposure from the severity of insomnia, capture dose and duration more precisely, and determine whether heart failure risk rises across different patient subgroups. Randomized evidence would be the cleanest way to determine whether melatonin itself carries cardiovascular harm, but observational data can still help define who may be most vulnerable.
Until then, the message is straightforward: long-term melatonin use in chronic insomnia should not be considered automatically benign. A supplement often framed as a low-risk sleep aid now sits next to an unresolved cardiovascular safety question, and that question is too important to ignore.